
A multicenter study finds ursodeoxycholic acid (UDCA) monotherapy effective in 81.5% of patients with cholestatic CHILI, offering a steroid-free alternative for managing immune checkpoint inhibitor-induced liver injury. Unlike corticosteroids, UDCA can be continued during ICI rechallenge, making it a promising long-term option with fewer side effects.
Like
Save
Share